REPLY
19.9.2023 09:31:27 CEST | Business Wire | Press release
Reply, a global systems integrator and consulting firm and Oracle Cloud Managed Service Provider, has received 4 Oracle Partner awards in recognition of its capabilities to deliver pioneering solutions, drive business value and customers success. The EMEA Cluster Partner Awards, announced at the Oracle EMEA Partner Appreciation Reception during Oracle CloudWorld in Las Vegas, have been awarded to the Reply companies specialized on Oracle technologies; Healthy Reply, Nimbus Reply and Red Reply.
The awards celebrate partners that foster innovation, accelerate business growth and create value to enable success for customers through technology integration and services built on Oracle Cloud Application, Oracle Cloud Infrastructure and Oracle Database technology. The Reply companies, focused on Oracle Cloud Infrastructure solutions and experts in end-to-end Oracle solutions, received the following EMEA Cluster Partner Awards:
- 2023 Customer Success Partner of Year – Europe South Tech / Cloud has been given to Nimbus Reply for the high customer satisfaction they have earned by empowering customers with innovative multi-cloud solutions. These resulted in a reduction of operational costs, an increase in application performance and improvements in system scalability, all while considering critical regulatory requirements.
- 2023 Customer Success Partner of Year – Europe North & East Tech / Cloud has been awarded to Red Reply for their capabilities to increase value to their end customers by streamlining solution implementation and management, improving human capital efficiency, reducing costs, minimizing technical debt, and achieving a measurable return on investment.
- 2023 Business Impact Partner of Year – Europe South Apps / SaaS has been assigned to Healthy Reply for developing exceptional solutions based on Oracle SaaS for the healthcare industry. The solutions developed allow to expedite projects and maximise the benefits of Cloud releases resulting invaluable for clients in managing specific processes and integrating with healthcare national systems.
- 2023 Innovation Partner of Year – Europe North & East Tech / Cloud has been granted to Red Reply for their capabilities to create pioneering solutions that empower customers and support these meeting their business goals and challenges. Red Reply have developed a solution that enables companies to seamlessly migrate their Legacy applications to the Cloud quickly. This rapid migration not only results in immediate cost savings but also enhances the company’s operational efficiency. Additionally, the system allows the transformation of Legacy Applications into Cloud-based Software-as-a-Service (SaaS) through a fully managed service, thus eliminating the need for extensive in-house development resources.
Filippo Rizzante, CTO at Reply, said, “We are delighted to have won these awards that reflect our continuous commitment in delivering cutting-edge Oracle solutions. Our ongoing investments in innovation and research & development, together with the expertise and capabilities of our companies dedicated to Oracle technologies allow us to support our customers better and to get the most from Oracle solutions.”
Reply, Oracle partner since 1997, with its companies dedicated to Oracle technologies, is best in class in Oracle Cloud Computing. With over 1500 certifications Oracle, Reply owns and manages one of the main European centers of competence. Reply is able to combine the full coverage of the entire supply chain, has experience in Oracle application suites, in Oracle technologies and in the main Oracle vertical solutions for the industry.
More information about Reply and Oracle partnership here.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Healthy Reply
Healthy Reply is the Reply Group company specialising in telemedicine, telemonitoring and the continuity of social welfare. Healthy Reply collaborates with public and private healthcare institutions and bodies, clinics and hospitals, social and healthcare facilities, insurance companies and banks, convention centres and enterprises, to design customised services that can guarantee continuous care and assistance. Healthy Reply has established strong competencies in Oracle ERPM Cloud solutions and continue to invest in expanding its offerings across all Oracle SaaS solutions.
Nimbus Reply
Nimbus Reply is the Reply Group company specialising in the delivery of Multi-Cloud solutions for the Health and Public Sector market. Composed of specialists with expertise in several Cloud Service Providers, Nimbus Reply promotes the adoption and evolution of the Cloud paradigm in the Public Sector, supporting end-to-end customers in the Journey to Multi-Cloud, in a Cloud Continuum perspective.
Red Reply
Red Reply is the Reply Group company specialising in Oracle Cloud Infrastructure with a focus on IaaS and PaaS solutions and offers Cloud Strategy and Migration, Application Development, Cloud / Application Management and Operations services. Red Reply is an expert in end-to-end Oracle solutions and one of first Oracle Cloud Managed Service Providers (MSP) in Europe. www.red.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919738958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
